Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis

Transplantation

Volumn 93, Issue 10, 2012, Pages 1017-1023

  Gustafsson, Sandra ^a   Ihse, Elisabet ^b   Henein, Michael Y ^a   Westermark, Per ^b   Lindqvist, Per ^a   Suhr, Ole B ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Amyloidosis hereditary; Cardiomyopathy; Echo cardiography; Transplantation liver; Transthyretin

Indexed keywords

AMYLOID;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; DETERIORATION; DIASTOLE; ECHOCARDIOGRAPHY; FAMILIAL AMYLOIDOSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART VENTRICLE FUNCTION; HEREDITARY TRANSTHYRETIN AMYLOIDOSIS; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTOLE; TISSUE DOPPLER IMAGING;

ADULT; AMYLOID; AMYLOIDOSIS, FAMILIAL; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; PREALBUMIN;

EID: 84861099373     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824b3749     Document Type: Article

References (34)

1. Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10: 160.
2. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36: 411.
3. Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl 1976; 590: 1.
4. Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994; 235: 479.
5. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113.
6. Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991; 40: 242.
7. Dubrey SW, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997; 64: 74.
8. Garcia-Herola A, Prieto M, Pascual S, et al. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Liver Transpl Surg 1999; 5: 246.
9. Olofsson BO, Backman C, Karp K, et al. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002; 73: 745.
10. Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: Implications for amyloid fibrillogenesis. Transplantation 1998; 66: 229.
11. Pomfret EA, Lewis WD, Jenkins RL, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 1998; 65: 918.
12. Bergstrom J, Gustavsson A, Hellman U, et al. Amyloid deposits in transthyretin-derived amyloidosis: Cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005; 206: 224.
13. Ihse E, Suhr OB, Hellman U, et al. Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med 2011; 89: 171.
14. Westermark P, Sletten K, Johansson B, et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990; 87: 2843.
15. Okamoto S, Wixner J, Obayashi K, et al. Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival. Liver Transpl 2009; 15: 1229.
16. Zhao Y, Henein MY, Morner S, et al. Residual compromised myocardial contractile reserve after valve replacement for aortic stenosis. Eur J Echocardiogr 2011; [Epub ahead of print, November 18, 2011].
17. Coley KC, Verrico MM, McNamara DM, et al. Lack of tacrolimusinduced cardiomyopathy. Ann Pharmacother 2001; 35: 985.
18. Johnston SD, Morris JK, Cramb R, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901.
19. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 2010; 75: 324.
20. Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007; 7: 235.
21. Ihse E, Stangou AJ, Heaton ND, et al. Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: An analysis on transplanted transthyretin T60A amyloidosis patients. Biochem Biophys Res Commun 2009; 379: 846.
22. Herlenius G, Wilczek HE, Larsson M, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: Results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77: 64.
23. Okamoto S, Zhao Y, Lindqvist P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid 2011; 18: 200.
24. Stangou AJ, Hawkins PN. Liver transplantation in transthyretinrelated familial amyloid polyneuropathy. Curr Opin Neurol 2004; 17: 615.
25. Ihse E, Ybo A, Suhr O, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008; 216: 253.
26. Koike H, Ando Y, Ueda M, et al. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci 2009; 287:178.
27. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440.
28. Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008; 263: 294.
29. Westermark P, Davey E, Lindbom K, et al. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem 2006; 108: 209.
30. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440.
31. Quinones MA, Otto CM, Stoddard M, et al. Recommendations for quantification of Doppler echocardiography: A report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167.
32. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072.
33. Kjaergaard J, Sogaard P, Hassager C. Right ventricular strain in pulmonary embolism by Doppler tissue echocardiography. J Am Soc Echocardiogr 2004; 17: 1210.
34. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165.